Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
April 30 2019 - 2:36PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immuno-therapeutics for the treatment of gut mediated
diseases, today announced that CEO Dr. Gary S. Jacob will present
at the ThinkEquity Conference on Thursday, May 2nd at the Mandarin
Oriental Hotel, New York, New York. Dr. Jacob’s presentation is
scheduled for 8:00-8:30 am Eastern time in the South Salon II
room. Management will also be holding one-on-one meetings
with investors and analysts during the conference.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian
microbiome biopharmaceutical company focused on developing and
commercializing orally delivered targeted polyclonal antibodies for
the treatment of inflammatory mediated and infectious diseases.
Immuron’s technology platform utilizes highly specific vaccines
administered to cows for the generation of hyperimmune
antibody-rich bovine colostrum, providing a means of antimicrobial
therapy without the drawbacks of antibiotics to treat gut-mediated
diseases. The Company currently markets Travelan® in Australia for
the prevention of Travelers’ Diarrhea, and markets Travelan® in the
U.S. and Canada as a dietary supplement for digestive tract
protection. Immuron’s lead clinical candidate, IMM-124E, is
presently in Phase II trials in alcoholic steatohepatitis (ASH) and
pediatric nonalcoholic fatty liver disease (NAFLD). Immuron
recently announced plans to pursue clinical development of
IMM-124E, its bovine polyclonal antibody drug candidate, through a
formal FDA registration pathway as a drug to prevent travelers’
diarrhea. Immuron’s second clinical-stage asset, IMM-529, targets
Clostridium difficile Infections (CDI), and is presently in a
clinical trial in C. difficile patients. The Company recently
announced plans to file an IND with FDA to focus further
development of the drug candidate specifically to treat patients
with recurrent disease.
For more information visit: http://www.immuron.com.
FORWARD-LOOKING STATEMENTS:This
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
COMPANY CONTACT:
Gary S. Jacob, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
AUS INVESTOR RELATIONS:
Peter Taylor
NWR Communications
Ph: +61 (0)4 1203 6231
peter@nwrcommunications.com.au
USA INVESTOR RELATIONS:
Dave Gentry - CEO
RedChip Companies, Inc.
US Ph: +1 (407) 491 4498
dave@redchip.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024